BiondVax Pharmaceuticals Overview

  • Founded

  • 2003

Founded
  • Status

  • Private

  • Employees

  • 26

Employees
  • Latest Deal Type

  • PIPE

  • Latest Deal Amount

  • $16.7M

  • Investors

  • 2

BiondVax Pharmaceuticals General Information

Description

BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. The company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic.

Contact Information

Website
www.biondvax.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly Angel backed
Primary Industry
Pharmaceuticals
Other Industries
Other Healthcare Services
Primary Office
  • Jerusalem BioPark Building, 2nd Floor
  • Hadassah Ein Kerem Campus
  • Jerusalem 7403618
  • Israel
+972 00-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BiondVax Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. PIPE 17-Jul-2019 $16.7M 0000 Completed Generating Revenue
7. 2PO 15-Sep-2017 000 000.00 000.00 Completed Generating Revenue
6. PIPE 02-Jan-2017 00.000 000.00 Completed Generating Revenue
5. 2PO 13-May-2015 00.00 000.00 000.00 Completed Generating Revenue
4. PIPE 01-Nov-2010 00.000 00.000 Completed Generating Revenue
3. IPO 18-Jun-2007 00000 00000 Completed Generating Revenue
2. Grant 23-Dec-2005 $1.1M Completed Generating Revenue
1. Angel (individual) Completed Generating Revenue
To view BiondVax Pharmaceuticals’s complete valuation and funding history, request access »

BiondVax Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufac
Pharmaceuticals
Jerusalem, Israel
26 As of 2022
0000
000000000 0000

000000

nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt
000000000000000
Beijing, China
0000 As of 0000
00000
000000 - 000 00000

000 00

labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris n
0000 000000000
Cambridge, MA
000 As of 0000
000.00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BiondVax Pharmaceuticals Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sinovac Corporation Beijing, China 0000 00000 000000 - 000 00000
000 00000000(00000 Corporation Cambridge, MA 000 000.00 00000000 000.00
00000000 000 Formerly VC-backed Somerville, MA 000 00000 000000000 00000
You’re viewing 3 of 3 competitors. Get the full list »

BiondVax Pharmaceuticals Patents

  • 30

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

BiondVax Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2015242154-A1 Compositions of multimeric-multiepitope influenza polypeptides and their production Granted 03-Apr-2014 000000000
AU-2015242154-B2 Compositions of multimeric-multiepitope influenza polypeptides and their production Active 03-Apr-2014 000000000 0
EP-3125931-A4 Compositions of multimeric-multiepitope influenza polypeptides and their production Pending 03-Apr-2014 000000000
JP-2017509657-A Compositions of multimeric multiepitope influenza polypeptides and their production Granted 03-Apr-2014 000000000 0
JP-6550072-B2 Compositions of multimeric multi-epitope influenza polypeptides and their production Active 03-Apr-2014 A61K39/12
To view BiondVax Pharmaceuticals’s complete patent history, request access »

BiondVax Pharmaceuticals Executive Team (8)

Name Title Board Seat Contact Info
Amir Reichman Chief Executive Officer & Board Member
Uri Ben-Or Chief Financial Officer
Elad Mark Chief Operating Officer, Operations
Shimon Hassin Ph.D Chief Administrative Officer
Tamar Ben-Yedidia Ph.D Chief Scientific Officer
You’re viewing 5 of 8 executive team members. Get the full list »

BiondVax Pharmaceuticals Board Members (8)

Name Representing Role Since
Amir Reichman BiondVax Pharmaceuticals Chief Executive Officer & Board Member 000 0000
Avner Rotman Ph.D BiondVax Pharmaceuticals Board Member 000 0000
Mark Germain Self Chairman & Board Member 000 0000
Morris Laster MD Self Board Member 000 0000
Samuel Moed BiondVax Pharmaceuticals Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

BiondVax Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BiondVax Pharmaceuticals Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Angels High Tech Investments Corporation Minority 000 0000 000000 0
Yorkville Advisors PE/Buyout Minority 000 0000 000000 0
To view BiondVax Pharmaceuticals’s complete investors history, request access »

Ready to get started?

Request a free trial